Industries de la santé

Pluristem Partners with CPC Clinical Research for Peripheral Artery Disease Study

Imprimer PDF

Écrit par Pluristem | 23 Juillet 2012

HAIFA, ISRAEL, July 18, 2012 -- Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE: PLTR), today announced that in anticipation of initiating a Phase II study using PLX-PAD cells for the treatment of Intermittent Claudication (IC), the company has recently entered into a collaborative agreement with CPC Clinical Research (CPC) for services related to enrolling and sustaining clinical sites...

Lire la suite... Ajouter un commentaire

Another Biotech Gets Absorbed: GSK Acquires HGS in a $3 Billion Deal

Imprimer PDF

Écrit par Globaldata | 19 Juillet 2012

LONDON, UK (GlobalData), 18 July 2012 - GlaxoSmithKline (GSK), the British pharmaceutical giant, acquired Human Genome Sciences (HGS) on Monday, July 16, 2012 for $14.25/share. On an equity basis this deal was worth about $3.6 billion; however, the final deal size was approximately $3 billion net of cash and debt. GSK paid a premium of 99% from when it offered its initial private...

Lire la suite... Ajouter un commentaire

Biobetters: The Big Draw in the Pharma Market

Imprimer PDF

Écrit par GBI | 16 Juillet 2012

NEW YORK (GBI Research), 13 July 2012 - Biobetters, drugs that have been improved since their initial incarnations, are demonstrating fantastic growth and leaving their originators well behind, states new research by pharmaceutical business specialists GBI Research.

The new report* explains how the more advanced drugs are far outstripping their biologic predecessors in terms of sales and...

Lire la suite... Ajouter un commentaire

New wet mill dramatically improves api milling capabilities

Imprimer PDF

Écrit par Quadro | 13 Juillet 2012

The Quadro Ytron® HV-Emulsifier Group Seri

Waterloo, Canada, July 11, 2012 - Size Reduction or Milling of APIs (Active Pharmaceutical Ingredients) is a key step in the drug development process. When milling an API, the developer requires a tight particle size distribution that ensures consistent drug substance and drug product quality. Traditionally, dry milling technologies such as...

Lire la suite... Ajouter un commentaire

Vexim poursuit son développement en Europe et s'implante en Italie

Imprimer PDF

Écrit par Vexim | 06 Juillet 2012

Création de Vexim Italie, deuxième filiale de Vexim après l'Allemagne


Toulouse, le 6 juillet 2012 - Vexim (FR0011072602 ALVXM), société de dispositifs médicaux  spécialisée dans le traitement mini-invasif des fractures vertébrales, annonce la création de sa filiale italienne à Milan. Disposant déjà d'une forte notoriété en Italie, la filiale va permettre à Vexim...

Lire la suite... Ajouter un commentaire

Despite Lofty Goals, Generating Antibiotic Incentives Now (GAIN) Act Falls Short

Imprimer PDF

Écrit par GlobalData | 03 Juillet 2012

LONDON, UK (GlobalData), 3 July 2012 - While the world focused on the fate of the Affordable Care Act, another important piece of healthcare legislation worked its way through Congress, the Prescription Drug User Fee Act (PDUFA) V. First introduced in 1992, PDUFA authorizes the FDA to collect fees from companies seeking approval of new drugs. The FDA uses these funds to hasten the drug...

Lire la suite... Commentaires (1)

Industries de la santé : Le SIDIV, membre actif d’ARIIS

Imprimer PDF

Écrit par SIDIV | 28 Juin 2012

Le Syndicat de l’Industrie du Diagnostic In Vitro (SIDIV), membre de droit de l’Alliance pour la Recherche et l’Innovation des Industries de Santé (ARIIS), y apporte une contribution active avec l’intention de promouvoir un environnement compétitif en France et de créer de la valeur dans le domaine de la recherche et de l’innovation pour les industries de santé.


Face aux enjeux...

Lire la suite... Ajouter un commentaire

Brazil Takes Control over its Pharma Market, but Generics Threaten to Cut Future Profits

Imprimer PDF

Écrit par GBI Research | 26 Juin 2012

NEW YORK (GBI Research), 26 June 2012 - Continuous support from the government is helping the Brazilian pharmaceutical market to grow at a compound annual growth rate (CAGR) of 9%, and to make its own mark on the global industry, says a new report by healthcare experts GBI Research.

The new report* states that Brazil has a population of around 190 million, representing a gigantic...

Lire la suite... Ajouter un commentaire

A Push for Personalized Medicine Encourages New Companion Diagnostics

Imprimer PDF

Écrit par GlobalData | 25 Juin 2012

LONDON, UK (GlobalData), 25 June 2012 - The in-vitro diagnostic industry is witnessing companion diagnostics emerge as the next big thing, as attention in the pharmaceutical industry shifts from blockbuster drugs to personalized medical treatment, says a new report by healthcare experts GlobalData.

The new report* states that the companion diagnostics industry is being spurred on as the...

Lire la suite... Ajouter un commentaire

Plus d'articles...

Information

Annuaires

Vitrines Sociétés

Voir toutes les vitrines